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ABSTRACT 
 
 
Intracellular bacteria invade mammalian cells to establish an infectious niche. The current work 
models adhesion and subsequent internalization strategy of pathogenic bacteria into mammalian 
cells to design a bacteriomimetic bioinvasive delivery system. We report on the surface 
functionalization of liposomes with a C-terminal fragment of invasin (InvA497), an invasion 
factor in the outer membrane of Yersinia pseudotuberculosis. InvA497-functionalized liposomes 
adhere to mammalian epithelial HEp-2 cell line at different infection stages with a significantly 
higher efficiency than liposomes functionalized with bovine serum albumin. Covalent 
attachment of InvA497 results in higher cellular adhesion than liposomes with physically 
adsorbed InvA497 with non-specific surface protein alignment. Uptake studies in HEp-2 cells 
indicate active internalization of InvA497-functionalized liposomes via β1-integrin receptor- 
mediated uptake mechanism mimicking the natural invasion strategy of Yersinia 
pseudotuberculosis. Uptake studies in Caco-2 cells at different polarization states demonstrate 
specific targeting of the InvA497-functionalized liposomes to less polarized cells reflecting the 
status of inflamed cells. Moreover, when loaded with the anti-infective agent gentamicin and 
applied to HEp-2 cells infected with Yersinia pseudotuberculosis, InvA497-functionalized 
liposomes are able to significantly reduce the infection load relative to non-functionalized drug- 
loaded liposomes. This indicates a promising application of such a bacteriomimetic system for 
drug delivery to intracellular compartments. 
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1. Introduction 
 
Functionalizing nanoparticles with peptide tags to initiate or enhance nanoparticles uptake by 
mammalian cells have significantly increased over the past years. Yet, impact on clinical praxis 
remains disappointing. One of the promising approaches, yet not much explored, is nanoparticle 
functionalization with bacterial outer membrane adhesins or invasins, i.e. proteins essential for 
cell adhesion and invasion of bacterial pathogens. Early trials indicate efficient cellular delivery 
using lectin [1, 2] and invasin (InvA497) [2-5] surface treated particles. This is the first in-depth 
mechanistic study investigating the cellular interaction of bacteriomimetic nanocarriers 
decorated with a truncated bacterial protein ligand in presence of the modeled bacterial 
counterpart. 
Yersinia species (Y. pseudotuberculosis and Y. enterocolitica) are facultative intracellular 
pathogens that elaborate several surface bacterial ligands involved in virulence, one of which is 
invasin (InvA).[6, 7] InvA is an outer membrane protein required for the efficient cellular uptake 
of enteric Yersinia species by binding to members of the β1-integrin receptor family (e.g. α5β1). 
Integrins are heterodimeric integral membrane proteins mediating communication between the 
extracellular environment and the cytoskeleton by binding to cytoskeletal components and either 
extracellular matrix proteins or other cell surface proteins. InvA binding to β1-integrins leads to a 
reorganization of the host cytoskeleton and formation of pseudopods that migrate around the 
bacteria and enclose them into a membrane-bound vacuole.[8] This study makes use of the 
detailed knowledge of the InvA-mediated cell adhesion and subsequent internalization of the 
Gram-negative bacterium Y. pseudotuberculosis to design a “bacteriomimetic” delivery system; 
InvA497-functionalized liposomes. 
Early trials to enhance uptake into mammalian cells on coupling InvA to nanoparticles [1, 3-5, 9] 
and microparticles [10, 11] used polymers. However, modelling the bacterial flexibility and the 
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bacterial membrane structure, liposomal carriers hold more promise. Yet, from the delivery 
aspect, the impact of InvA functionalization on rather more physiologically compatible, easily 
loadable nanoparticulate systems for therapeutic applications remains to be shown. To the best of 
the authors’ knowledge, this is the first study reporting the potential of bacteriomimetic 
liposomes functionalized with a C-terminal fragment of the InvA protein (Inv497) and their 
uptake mechanism and kinetics in comparison to their natural bacterial counterparts. The system 
invasion efficacy was challenged in presence of Y. pseudotuberculosis, the bacteria expressing 
InvA. As a proof of concept, the therapeutic effect of InvA497-functionalized liposomes was 
demonstrated when loaded with the hydrophilic and poorly permeable aminoglycoside antibiotic 
gentamicin as a model anti-infective. Gentamicin-loaded InvA497-functionalized liposomes  
were employed in a human epithelial cell model preinfected with an invasive Y. 
pseudotuberculosis serotype O:3 strain, and assessed for their ability to affect intracellular 
bacterial killing. 
 
 
2. Experimental Section 
 
 
2.1. Overexpression and Purification of the Cell-surface Exposed C-terminal Domain of Invasin 
(InvA497) 
 
InvA497 was extracted and purified according to previous studies.[6] Two liters of E. coli BL21 
expressing the His-tagged C-terminal 497 amino acids of InvA (His6-InvA497) from Y. 
pseudotuberculosis were grown at 37 °C in Luria broth medium (LB) (Carl Roth GmbH, 
Karlsruhe, Germany) to an A600 = 0.4. The culture temperature was then shifted to 17 °C and 
grown to an A600 = 0.6. Isopropyl-b-D-thiogalactopyranoside was added to a final concentration 
of 100 μM to induce the expression His6-InvA497. Cells were allowed to grow overnight at 17 
°C, followed by washing in order to produce a cell pellet. The cell pellet was then resuspended in 
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50 ml cold lysis buffer containing 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole (pH 8) 
together with a protease inhibitor cocktail containing 5 mM phenylmethylsulfonyl fluoride, 10 
mM pepstatin, 10 mM E64 protease inhibitor, 20 mM leupeptin and 10 mM chymostatin. The 
cells were disrupted using a french press (2x at 1000 psi). The His6-InvA497 protein was  
purified by affinity chromatography with Ni-NTA Agarose (Qiagen, Venlo, Limburg, The 
Netherlands), eluted in elution buffer containing 50 mM NaH2PO4, 300 mM NaCl and 250 mM 
imidazole (pH 8) and dialyzed twice against 10 mM Tris buffer (Trisaminomethane, pH 8) 
containing 300 mM NaCl. Protein concentrations were determined by the Bradford protein assay 
(Pierce, Rockford, IL, USA). 
 
 
2.2. Preparation of Fluorescent Liposomes Containing Carboxylic groups 
 
 
Liposomes were prepared by lipid film hydration followed by membrane extrusion to obtain 
monodispersed unilamellar vesicles following a previously published method after 
modification.[12] In detail, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (Lipoid 
GmbH, Ludwigshafen, Germany), cholesterol (Sigma-Aldrich, Steinheim, Germany) and 1,2- 
dihexadecanoyl-sn-glycero-3-phosphoethanolamine-N-(glutaryl) (sodium salt) (Avanti Polar 
Lipids, Inc., Alabaster, USA) in a molar ratio of 6:3:0.6 were dissolved in 5 ml chloroform- 
methanol mixture, 2:1. A 100 μl of 0.5 mg/ml choroformic solution of the fluorescent dye “1,2- 
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
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(ammonium salt)” (Avanti Polar Lipids, Inc., Alabaster, AL, USA) was added. The final lipid 
mixture (19.2 mM) was dried in a rotary evaporator (Büchi, Essen, Germany) at 70 °C, 200 mbar 
and 145 rpm for 1 h to form a thin uniform lipid film. Complete evaporation of the remaining 
solvents was achieved by further heating at the same temperature under a pressure of 40 mbar 
with 145 rpm for further 30 min. The lipid film was then hydrated with 5 ml 100 mM MES (4- 
Morpholineethanesulfonic acid) buffer, pH 6 at a speed of 55 rpm for 1 h at 50 °C. Unilamellar 
liposomes were prepared by extruding the resulting multilamellar vesicles through 200 nm 
polycarbonate membrane (AMD Manufacturing Inc., Ontario, Canada) at 60°C under high 
pressure using nitrogen flow in a sealed stainless steel jacketed extruder (liposoFast L-50, 
Avestin, Mannheim, Germany). Liposomal dispersions were diluted 1:10 with MES and stored at 
4 °C prior to further use. 
 
 
2.3. Liposome Surface Functionalization 
 
 
Liposomes were surface functionalized with either InvA497 or bovine serum albumin (BSA; 
Sigma Aldrich, Steinheim, Germany). A volume of 2 ml liposomal dispersion was incubated 
overnight with 300 μl of crosslinking agent, consisting of 48 mM EDC/19 mM NHS (EDC: N- 
(3-dimethylaminopropyl)-Nˊ-ethylcarbodiimide hydrochloride; Sigma Aldrich, Steinheim, 
Germany; NHS: N-hydroxysuccinimide 99 %; Carbolution Chemical GmbH, Saarbrücken, 
Germany) in MES buffer (pH6) with gental shaking at room temperature. Liposomes were 
centrifuged (Rotina 420R; Hettich Zentrifugen, Tuttlingen, Germany) in Centrisart® tubes 
300,000 MWCO (Sartorius, Goettingen, Germany) at 3270 g, 4 °C for 30 min to remove excess 
free reagent followed by three successive washing steps during which the MES buffer was 
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gradually exchanged with phosphate buffer saline (PBS) (Sigma Aldrich, Steinheim, Germany), 
pH 7.4 . The total volume was then completed to 2.5 ml with PBS. A 300 μl volume of 1 mg/ml 
InvA497 or BSA in PBS was added and coating process was continued overnight in ice bath with 
gentle shaking. This was followed by centrifugation and washing steps in Centrisart® tubes 
300,000 MWCO to remove unbound protein. 
 
 
2.4. Measurement of Colloidal Characteristics 
 
 
Liposomes, 0.2 µM, were characterized for mean diameter, polydispersity index (PDI) and zeta 
potential using the ZetaSizer Nano (Malvern Instruments Ltd., Malvern, UK) before and after 
covalent protein attachment. Colloidal stability of liposomes in biological media was also 
investigated. Measurements were performed in triplicates. 
 
 
2.5. Determination of Protein Functionalization Efficiency 
 
 
The amount of InvA497 or BSA coupled to the surface of liposomes was quantified using a 
bicinchoninic acid (BCA) kit, in accordance with the manufacturer’s instructions (QuantiProTM; 
Sigma-Aldrich, Steinheim, Germany). This assay is suitable to measure even proteins covalently 
bound to surfaces.[13] Absorbance was measured at 562 nm and concentration was determined 
reference to preconstructed calibration curves of InvA497/BSA in the presence of control 
liposomes to correct for lipid interference. Protein quantification was also performed using SDS- 
PAGE and western blot following a protocol by Schulze et al.[14] 
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2.6. Cell Cultures and Treatments 
 
 
The human epithelial type 2, HEp-2 cell line (CCL-23 
TM
; ATCC, Manassas, VA, USA) 
originating from a human laryngeal carcinoma and expressing the β1 integrin receptor was 
cultivated in Roswell Park Memorial Institute medium (RPMI 1640) (Gibco by life 
technologies
TM
, Paisley , UK) supplemented with 10 % fetal calf serum (FCS) (Lonza, Cologne, 
Germany) and kept in culture for a maximum of 2 months after thawing. 
 
Caco-2 cells, clone C2Bbe1 (CRL-2102™; ATCC, Manassas, VA, USA) were cultivated in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % FCS and 1 % non- 
essential amino acids (PAA cell culture company, Pasching, Austria) and used at passages 58-72. 
 
 
2.7. Cell Viability Assay 
 
 
An ATP bioluminescent assay (ViaLight™ Plus, Lonza, Basel, Switzerland) was used to 
determine the viability of both HEp-2 and Caco-2 cells in response to treatment with liposomal 
formulations. This assay is based on enzymatic determination of ATP present in all metabolically 
active cells. Luciferase enzyme is employed to catalyze the formation of light from ATP and 
luciferin, the emitted intensity of which is linearly related to the ATP concentration.[15] A 
volume of 100 μl of a series of 0.12-1.92 μM liposomal dispersions was tested on confluent 
HEp-2 cells, and confluent and 50 % confluent Caco-2 cells seeded in 96-well plates (Greiner 
bio-one, Frickenhausen, Germany). InvA497-functionalized and non-modified liposomes were 
tested in parallel. HEp-2 and Caco-2 cells were incubated with the liposomes for 4 and 8 h, 
respectively. Cell lysis reagent
®
, 50 μl/well, was added to extract ATP from the cells. A volume 
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of 100 μl of each of the cell lysate and ATP monitoring reagent Plus® were incubated in 96-well 
white walled luminometer plate (Optiplate™-96; PerkinElmer Inc., Waltham, MA, USA) for 2 
min at  room temperature in  the dark. Bioluminescence was measured (Tecan Deutschland 
GmbH, Crailsheim, Germany). Cells grown in culture medium only were considered as negative 
control (100 % cell viability) and others incubated with Triton X-100 (2 % w/v) were used as 
positive control (0 % cell viability). Percentage cell viability was calculated based on five 
replicates as shown in Equation 1. 
 
 (1) 
 
In parallel, ATP controls in concentrations of 1.5 and 0.015 μM were prepared. A 50 μl volume 
of each of the control and the liposomes was incubated together with 100 μl ATP monitoring 
reagent Plus
® 
and bioluminescence was measured to check for wavelength interference  in 
absence of cells. 
 
 
 
2.8. Cell-adhesion Experiments 
 
 
Cell adhesion of InvA497-functionalized liposomes versus liposomes with physically adsorbed 
InvA497 was tested. Amount of physically adsorbed protein was equivalent to covalently 
coupled protein as determined by Bradford assay (Thermo Scientific, MA, USA). Appropriate 
control liposomes were also employed in parallel; BSA-functionalized liposomes and liposomes 
with physically-adsorbed BSA. 
One day prior to adhesion experiments, HEp-2 cells were seeded in 8 well μ-slides (Ibidi, 
Martinsried, Germany) at a density of 1x10
4 
cells/well. Concomitantly, constitutively GFP- 
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expressing Y. pseudotuberculosis was cultivated in LB medium (lysogeny broth, Carl Roth 
GmbH, Karlsruhe, Germany). 
Three sets of adhesion experiments were performed in parallel, at a temperature of 25 °C. In the 
first set of experiments a late stage of infection was simulated - cells were infected with bacteria 
(50 μl of 1x106 bacteria/well) 30 min before addition of 50 μl/well of liposomes. In the second 
experimental set, simulating an early infection stage, both bacteria and liposomes were applied to 
cells simultaneously. For the third experimental set, simulating the healthy state, liposomes were 
applied to cells in absence of any bacterial treatment. Subsequently, cells were washed three times 
with PBS and incubated in binding buffer (RPMI 1640 medium supplemented with 20 mM        
of HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7) and 0.4 % BSA) before 
addition of bacteria and/or liposomes. Cells were incubated for 1 h with test liposomes at a 
concentration of 4x10
4 
liposomes/ml, after which culture medium was removed and cells were 
washed three times with PBS. Cells were then fixed using 4 % paraformaldehyde in PBS for 10 
min, and blocked and permeabilized by incubation with blocking buffer (5 % goat serum, 0.1 % 
Triton X-100 in PBS) for 60 min. Cell nuclei were stained by DAPI (4',6-diamidino-2- 
phenylindole, Carl Roth, Karlsruhe, Germany). 
Cell adhesion was examined using fluorescence microscopy (Zeiss Axioskope; Zeiss, Jena, 
Germany) followed by image analysis by the freeware ImageJ (http://rsbweb.nih.gov/ij/). Image 
analysis was based on a previously established method in which the number of pixels due to 
liposomal fluorescence was calculated. The number of liposomes was estimated based on the  
area of a single diffraction-limited fluorescent spot; π(rxy)2 (Equation 2),[16-18] 0.359 μm2 in 
this study based on λ (emission wavelength for rhodamine) = 564nm and NA (numerical aperture 
of the optical lens) = 1.1. 
        (2) 
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2.9. Cell Uptake Studies 
 
 
In preparation for uptake assays, InvA497-functionalized and control non-modified liposomes 
(1.92 μM) were centrifuged at 20000 g for 30 min at 4 °C, redispersed in culture medium and 
sterilized upon filtration through 0.2 μm membrane filters (Sartorius Stedim Biotech GmbH, 
Goettingen, Germany). Cells previously seeded in 24-well imaging plates (Zell-Kontakt, Nörten- 
Hardenberg, Germany) to approximately 80 %, and 50 or 90 % confluency for HEp-2 and Caco- 
2 cells, respectively, were washed with PBS in order to remove culture medium. 
 
 
2.9.1. Relative Liposomal Uptake 
 
 
HEp-2 and Caco-2 cells were exposed to liposomes (500 μl/well) for 1, 4 or 8 h at 37 °C, 5 % 
CO2. Following incubation, cells were washed with PBS and fixed with 4 % paraformaldehyde. 
Cells were then stained with fluorescein wheat germ agglutinin (Flu-WGA, 6.25 μg/ml, Vector 
Laboratories, Burlingame, CA, USA) and DAPI (6.66 ng/ml) in order to allow for visualization 
of cell membranes and cell nuclei, respectively. Imaging plates were protected from light and 
stored at 4 °C until analysis via fluorescence imaging, which was performed using an inverted 
confocal-multiphoton laser scanning microscope (ZEISS LSM 510 META, Carl Zeiss, Jena, 
Germany). The objective used was a water immersion lens 40 x (NA=1.1). Wavelengths of 543 
nm, 488 nm and 720 nm were used for excitation of rhodamine-labelled liposomes, Flu-WGA- 
labeled cell membranes and DAPI-labeled nuclei, respectively. Z-stacks of cells were taken with 
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step sizes of 0.8 μm, and with optical scans of an area of 0.22 x 0.22 μm2. The gain settings were 
adjusted for each measurement individually. For each captured z-stack, optical layers 
incorporating cell-internalized liposomes were chosen and a z-projection image of the red 
channel (red fluorescence due to liposomes) was developed using ImageJ. The number of pixels 
was computed and converted into weighted number of liposomes as described previously [16, 
17] and as briefly referred to in the methodology of the adhesion experiments. 
 
 
2.9.2. Liposomal Uptake Kinetics 
 
 
In addition to analysis of uptake using fixed cells, live cell imaging was also undertaken in order 
to obtain further information regarding the kinetics of liposomal internalization. HEp-2 cells 
were seeded in 8-well μ-slides to about 80 % confluency, washed with cell culture medium, 
stained with Flu-WGA (6.25 μg/ml) for 5 min at 37 °C to facilitate cell membrane visualization, 
and washed again before liposomal application. μ-slides were transferred into an incubation 
chamber of the confocal microscope with a constant temperature of 37 °C and 5 % CO2 level to 
maintain cell viability throughout the experiment. An area of interest was then selected and 
imaging was performed using the same settings as indicated above, with the exception of the 
optical image area which in this case was 0.27 x 0.27 μm2. Z-stacks were sequestered at different 
time intervals (1, 2, 3 and 4 h). The thickness of the optical layer was kept as 0.8 μm. ImageJ was 
used to develop z-projection images of the red channel of the optical layers in the captured z- 
stacks followed by pixel analysis. The weighed number of liposomes was plotted versus time to 
determine cell uptake kinetics. To get more information on uptake kinetics within the first hour 
of liposome application, cell uptake experiments with 10 and 30 min incubation periods were 
conducted using the same set-up; however in this case cells were fixed before imaging as 
13  
described above, in order to avoid possible photobleaching-associated inaccuracies resulting 
from continuous laser exposure of the treated cells on Z-sectioning. 
 
 
2.9.3. Mechanistic Uptake Studies 
 
 
In order to assess the mechanism of liposomal uptake into HEp-2 cells, experiments were 
conducted at 37 °C or 4 °C for a period of 4 h. An additional set of mechanistic studies were also 
carried out in which cells were incubated with the potential uptake inhibitors anti-integrin β1- 
antibody (1:100 dilution), NPC-15437 dihydrochloride, monoclonal anti-CD29 (Sigma Aldrich, 
Steinheim, Germany) (1 μM) and Akt inhibitor VIII (Calbiochem, San Diego, CA, USA) (25 
μM) for 1 h at 37 °C before washing, liposome addition, and a further 4 h incubation. All 
inhibitors were dispersed in RPMI supplemented with 20 mM HEPES buffer (pH 7) and 0.4 % 
BSA. Cells were then prepared for analysis (washing, fixing and staining) and visualized using 
fluorescence imaging as described above for relative liposomal uptake studies. 
 
 
2.10. Determination of Anti-infective Efficacy 
 
 
 
In order to assess the ability of the bacteriomimetic carrier to function as an effective 
intracellular delivery system, InvA497-functionalized liposomes were loaded with the poorly 
permeable anti-infective gentamicin, characterized for colloidal properties and the amount of 
entrapped drug, and finally applied to an infected epithelial cell model. 
Gentamicin-loaded liposomes were prepared by hydrating the lipid films (described earlier in the 
methodology followed to prepare drug-free liposomes) with 5 ml of gentamicin solution (10 
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mg/ml in PBS). This was followed by surface functionalization with InvA497. The incubation 
time with the crosslinking agent (EDC/NHS) was limited to 3 h to reduce the possibility of drug 
release overnight. The amount of gentamicin entrapped within liposomes was quantified using an 
O-phthaldialdehyde-(OPA) based fluorometric assay (Sigma-Aldrich, Steinheim, Germany) 
subsequent to a lipid extraction, as previously described.[19] The fluorescence of extracted 
samples was measured in a plate reader (Genios Pro, Tecan, Germany) with an excitation 
wavelength of 344 nm and an emission wavelength of 450 nm. The amount of gentamicin 
entrapped within liposomes was then calculated with reference to the fluorescence intensity of 
standard gentamicin solutions. 
An in vitro killing assay was conducted using epithelial cells of the β1 integrin receptor- 
expressing HEp-2 cell line. Cells were infected with an invasive Y. pseudotuberculosis serotype 
O:3 strain. For this, the culture medium of HEp-2 cells (previously seeded one day before the 
experiment in a 24 well-plate) was exchanged with binding buffer containing Y. 
pseudotuberculosis at 1:25 multiplicities of infection. Cell culture plates were then centrifuged at 
6708 g for 5 min (Eppendorf 5810 R Centrifuge, Hamburg, Germany) to sediment bacteria onto 
the cells. Cells and bacteria were then incubated for 1 h at 37 °C and 5 % CO2 to allow for 
binding and penetration of the bacteria into the cells. A 1 h-cell incubation with 50 μg/ml of free 
gentamicin in binding buffer was a key step in order to kill any remaining extracellular bacteria. 
Infected cells were then washed twice with PBS to eliminate both gentamicin and killed 
extracellular bacteria, leaving HEp-2 cells containing intracellular Y. pseudotuberculosis. 
Infected cells were then treated for 2 h with gentamicin-loaded liposomes functionalized with 
InvA497 (I-GL) containing 50 μg/ml gentamicin. Drug-free liposomes (1.3 mM); both non- 
modified (L) and InvA497-functionalized drug-free liposomes (I-L), and gentamicin loaded 
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liposomes (GL) containing 50 μg/ml gentamicin served as control formulations. Following 
liposomal treatment, infected cells were washed twice with PBS and lysed with 200 μl lysis 
buffer containing 0.1% Triton X-100. Remaining intracellular bacteria following liposomal 
incubation were quantified after plating cell lysates on LB plates for 48 h at 25 °C. Results were 
expressed as a percentage of bacterial killing relative to untreated cells (blank, B). ANOVA 
followed by Post-hoc analysis were performed to determine the statistical significance of 
observed differences. Differences were considered to be significant (*) at a P-value < 0.05. 
 
 
3. Results and Discussion 
 
 
 
3.1. Physico-chemical characteristics of liposome formulations 
 
 
Monodisperse phospholipid fluorescent liposomes containing carboxylic groups were prepared 
by lipid film hydration method. Cholesterol in the bilayer was incorporated as a membrane 
stabilizer increasing the glass transition temperature.[20, 21] 
To decorate the liposomal surface we used a C-terminal fragment of the InvA protein (InvA497) 
of Y. pseudotuberculosis an important protein which is required for efficient invasion of this 
bacterium into human cells.[8] A prerequisite for binding to the integrin α5β1-receptor is that the 
C-terminal carboxylic group of InvA497 remains free, non-substituted and directed towards the 
outer part of the protein corona.[8] This was achieved via a two-step surface functionalization of 
liposomes in which the carboxylic groups on the liposomal surface were first activated by 
EDC/NHS mixture. EDC reacts with the carboxylic group, forming an amine-reactive O- 
acylisourea intermediate which subsequently reacts with an amine group forming an amide bond. 
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However, the O-acylisourea intermediate is very unstable and susceptible to hydrolysis resulting 
in low coupling efficiency. The addition of sulfo-NHS stabilizes the intermediate by converting 
it to a semi-stable amine-reactive NHS ester, thereby increasing the coupling efficiency.[22-24] 
In the second step, after washing off excess of non-covalently bound EDC, activated carboxylic 
groups on the liposomes react with the N-terminus of the surface-exposed InvA497 domain 
leaving the C-terminus of the adhesion molecule free for the interaction with the β1-integrin 
receptors. This two-step procedure of protein coupling avoided loss of InvA497 activity as well 
as interprotein conjugation leading to protein supramolecules or even aggregates.[24] 
Liposomes were functionalized with InvA497 or BSA without any observed aggregation. Results 
of particle characterization are shown in Table 1. Size diameter of liposomes was around 143  
nm. The zeta potential was in the range of -20 to -43 mV. Liposomes were found stable on 
overnight incubation in culture media at 37 °C with a PDI of approximately 0.05. Increase in zeta 
potential was observed upon protein coating indicating higher stability due to steric hindrance by 
the protein corona. The protein coating efficiencies determined by surface protein quantification 
using BCA and western blot assays were found comparable (Table 1). 
 
 
3.2. Cell viability study 
 
 
 
For the cell-liposomes association experiments, it was important to ensure that cell adhesion and 
uptake measured is induced by non-cytotoxic concentrations of liposomes. Furthermore, for 
biomedical purposes, especially for clinical applications,  toxicity is a critical factor  in the 
evaluation of their potential.[25] As the InvA497-functionalized liposomes are intentionally 
engineered  to  interact  with  and  invade  the  cells,  it  is  important  to  ensure  that  this 
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functionalization is not causing any cytotoxic effect. First, potential nanoparticle-dye 
interferences must be considered to avoid false-positive and false-negative results.[26, 27] No 
interference was observed measuring luminescence of ATP standards in the presence of 
liposomes (Figure S1). Figure 1 shows the viability of HEp-2 and Caco-2 cells after incubation 
with uncoated as well as InvA497-functionalized liposomes. No significant difference in cell 
viability was observed for non-modified liposomes or InvA497-functionalized liposomes 
compared to non-treated control cells, indicating that InvA497-functionalized liposomes are 
suitable and efficient drug delivery tools. The increased mean viability of cells after liposome 
exposure (Figure 1) could be due to cell proliferation over time in presence of phospholipids and 
cholesterol naturally present in cell membranes of mammalian cells.[28] Although only the small 
C-terminal portion of InvA is used for liposome coating, we cannot fully exclude 
immunostimulatory reactions via the production of inflammatory cytokines [29] and future tests 
are required to study the effects of the particles on the human immune system. 
 
 
3.3. Cell-adhesion experiments: InvA497-functionalized liposomes promote tight adhesion to 
human epithelial cells 
 
 
Challenging experiments were designed to investigate the ability of InvA497-functionalized 
liposomes to adhere to β1-integrin expressing HEp-2 cells in the presence of InvA-expressing Y. 
pseudotuberculosis. Such studies were carried out at a temperature of 25 °C, conditions under 
which cell adhesion but no InvA-mediated invasion into host cells was observed.[2, 5] Liposome 
formulations with covalently-coupled InvA497 or BSA (as a negative control, non-invasive 
protein) were employed; in addition, liposomes with surface-adsorbed InvA497 and BSA were 
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used. Three different experimental sets were performed in which (i) only InvA497- or BSA- 
coated liposomes were added to HEp-2 cells in total absence of Y. pseudotuberculosis (healthy 
state), (ii) in which the liposomes were added simultaneously with InvA-expressing Y. 
pseudotuberculosis (mimicking early stage infection conditions), and (iii) in which the liposomes 
were added after infection with InvA-expressing Y. pseudotuberculosis (representing a late 
infection stage). 
Liposomes with either physically adsorbed or covalently-linked surface BSA did not show 
significant adhesion to HEp-2 cells shown by fluorescence imaging (Figure 2a,b) and by 
calculating the number of cell-associated liposomes (Figure 2c). InvA497 functionalization 
resulted in significantly higher levels of cellular adhesion. Only 2-5 fold more cell-associated 
liposomes were observed with physically adsorbed InvA497-coated liposomes, while liposomes 
with covalently linked InvA497 resulted in a 32-38 fold increase in adhesion to HEp-2 cells 
relative to control liposomes covalently-linked with BSA (Figure 2c). This difference can likely 
be attributed to an optimal orientation of InvA497 in this formulation which allows the 
projection of the C-terminal region of InvA from liposomal surfaces facilitating integrin 
receptor-mediated adhesion (refer to Section 2.1), and testifies the successful design of a 
bioinvasive carrier with bacteriomimetic traits. 
With respect to cell adhesion of liposomal formulations in simulated healthy, early or late 
infection stages, it was seen that simultaneous or pre-exposure of HEp-2 cells to the InvA- 
expressing bacterium Y. pseudotuberculosis led to a reduction in adhesion of InvA497 liposome 
formulations relative to adhesion under sterile conditions. This demonstrates that InvA497- 
modified liposomes compete with InvA-expressing bacteria for β1-integrin-mediated cell 
adhesion (and eventually invasion). The fact that measurable levels of liposomal adhesion were 
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still noted even following pre-incubation of HEp-2 cells with InvA-expressing bacteria is 
however an encouraging observation. This suggests that these bacteriomimetic carrier can not 
only be used for intracellular delivery of anti-infective compounds as a prophylactic or early 
infection stage measure, but also as therapy of established intracellular infections which may be 
initiated by the identical adhesion/invasion mechanism. 
 
 
3.4. Cell uptake kinetics and internalization mechanism into HEp-2 cells 
 
 
Next, we determined the capacity of covalent InvA497-functionalization (as the optimal noted 
method of InvA497 attachment) to promote invasion/uptake of liposomes into HEp-2 cells and 
studied the uptake kinetics and the molecular internalization mechanism of InvA497- 
functionalized liposome uptake. 
Cellular uptake of InvA497-functionalized liposomes was compared to that of both non-modified 
liposomes and BSA-functionalized liposomes as control formulations 1 and 4 h after application 
of the liposomes to HEp-2 cells. Knowing that the recycling time of α5β1 integrin is 30 min [30], 
the chosen time frame is appropriate covering several receptor cycles. Yet, the incubation time is 
considered short enough to minimize non-specific uptake of cells through fluid-phase 
endocytosis [31]. More importantly, a time frame of 4 h was chosen according to the 
internalization timeline of Y. pseudotuberculosis into HEp-2 cells [32]; whereas most cell-
attached bacteria are internalized after 4 h. 
Representative confocal-multiphoton images are shown in Figure 3a and results of image 
analysis of the sequestered z-stacks are given in Figure 3b. Minimal induced cell uptake was 
observed for control liposomes likely resulting from non-receptor-mediated fusion of liposomal 
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and HEp-2 cell membranes.[33] Cell uptake was induced upon InvA497 coupling and the 
number of intracellular liposomes increased significantly over time. 
To determine uptake kinetics, cell uptake into living HEp-2 cells was tracked over 4 h (Figure 
4a). As the previously conducted fixed time point experiments demonstrated no difference in 
uptake between non-modified and BSA-functionalized liposomes (Figure 3), only non-modified 
liposomes were employed as the sole control formulation in all the following experiments. Z- 
projection images clearly showed that both non-modified and InvA497-functionalized liposomes 
accumulated within living cells over time, whereby the overall signal obtained for the InvA497- 
functionalized liposomes was significantly higher at each time point. (Figure 4a). In order to 
determine numbers of internalized liposomes, a pixel analysis of live cell images, as well as of 
cell samples incubated with liposomes for periods of 10 and 30 min followed by cell fixation (in 
order to avoid photobleaching and imaging inaccuracies resulting from continuous laser  
exposure on Z-sectioning) was conducted (Figure 4b). This analysis demonstrated that the overall 
number of internalized Inv497-coated liposomes was significantly higher at each time point 
compared to the controls. Moreover, the average uptake rate of InvA497-functionalized 
liposomes (507 liposomes/h) was approximately 7-fold higher relative to the control lipsomes 
(70 liposomes/h) (Figure 4b). Further analysis of the uptake profile of InvA497-functionalized 
liposomes showed that the InvA497-mediated uptake can be divided into three distinct phases: 
(i) an initial, exponential phase describing a rapid receptor-mediated internalization of 
liposomes; (ii) a plateau, typically indicative of saturation of uptake-mediating receptors [34]; 
followed by (iii) a linear uptake process characterized by a linear uptake rate. 
To further characterize the uptake mechanism, HEp-2 cells were incubated with InvA497- 
functionalized and control liposomes at 4 °C and 37 °C to determine relative liposomal uptake 
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(Figure 5a). At 4 °C, energy-dependent uptake (e.g. endocytosis) is generally greatly 
reduced.[35] In fact, a significantly higher number of intracellular Inv497-coated liposomes were 
detectable at 37°C compared to 4°C, whereas no significant difference in cell uptake was 
observed with control liposomes (Figure 5a). This indicates that Inv497-functionalized 
liposomes are internalized by a receptor-specific uptake process. However, a minor extent of cell 
uptake of InvA497-functionalized liposomes appears to interact with the cell membrane non- 
specifically and facilitates uptake by some energy-independent processes, as shown by 
experiments done at 4°C (Figure 5a). 
Finally, to verify that the cell uptake mechanism of InvA497-functionalized liposomes is 
receptor-specific and β1-integrin-mediated, cell uptake inhibition experiments were conducted. In 
the first instance, anti-integrin β1-antibody was incubated with HEp-2 cells before the addition of 
InvA497-functionalized liposomes. As shown in Figure 5b, a significant reduction in liposome 
uptake was observed in the presence of the anti-integrin β1-antibody, indicating that uptake of 
InvA497-functionalized 497 occurs via β1-integrin receptors [6]. Two inhibitors reported to 
reduce the InvA-triggered cell uptake of Y. pseudotuberculosis, Akt inhibitor VIII and protein 
kinase C (PKC) inhibitor NPC-15437,[32, 36] were employed to prove β1-integrin-mediated 
liposome uptake. The serine/threonine kinase Akt and PKC are activated in response to many β1- 
integrin-initiated signaling processes, including InvA-mediated uptake of Y. 
pseudotuberculosis.[36] Inhibition of either Akt or PKC resulted in a significant reduction in 
InvA497-functionalized liposomal cell entry, confirming their β1-integrin-mediated uptake 
(Figure 5b). Application of the selective inhibitors reduced cell uptake to 22-29 %, similar to 
what has been shown for InvA-mediated uptake of Y. pseudotuberculosis.[36] This clearly 
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demonstrates that Inv497-coated liposomes enter via β1-integrin-mediated uptake and verifies 
bacteriomimetitic characteristics of the developed InvA497-functionalized carrier. 
 
 
3.5. Potential applications of bacteriomimetic nanocarriers in simulated states of inflammation 
and infection 
 
3.5.1. Targeting Inflamed β1-integrin Expressing Intestinal Mammalian Cells: Non-polarized 
versus Polarized Caco-2 cells 
 
 
With particular respect to the human intestinal epithelium, it has been demonstrated that invasion 
by InvA-expressing Y. pseudotuberculosis occurs exclusively via interaction with β1-integrins 
found on Microfold (M) cells,[37] as such receptors are not expressed on the apical side of 
differentiated polarized enterocytes.[38] However, under specific conditions (e.g. during 
intestinal inflammatory bowel disease or a bacterial infection) tight junctions open and β1- 
integrins become more accessible on the apical surface of the enterocytes.[39] Knowing that 
 
Caco-2 cell line is a well-established model for the human intestinal barrier [40, 41], uptake into 
 
non-polarized and polarized Caco-2 cells was investigated in order to mimic the receptor 
 
distribution pattern in inflamed and healthy enterocytes, respectively. Cells at 50 % confluency 
express β1-integrins on their apical surface (resembling the inflamed state), whereas cells grown 
to over 90 % confluency reduce the expression of the InvA receptor on the apical side according 
to the healthy state.[42] Application of InvA497-functionalized liposomes was seen to result in 
uptake only in the case of sub-confluent Caco-2 cells (Figure 6). Some adhesion of InvA- 
functionalized liposomes on polarized cells was also observed, however, this weak attachment 
was not sufficient to promote liposomal internalization. No uptake of the control liposomes was 
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observed regardless of the Caco-2 cell confluency level, demonstrating a clear advantage of the 
InvA497-functionalized system in to less-confluent enterocytes mimicking the inflamed state. 
The data suggest that InvA-mediated targeting of the β1-integrin receptors could be exploited to 
develop drug delivery carriers targeting the inflamed intestinal epithelium. 
 
 
3.5.2. Anti-infective Efficacy Studies 
 
 
The ability of such a bacteriomimetic concept to facilitate effective intracellular delivery of the 
poorly permeable anti-infective agent gentamicin was investigated. For this purpose, HEp-2 cells 
infected with an invasive Y. pseudotuberculosis serotype O:3 strain [43-45] were employed. 
Infected HEp-2 cells were treated with gentamicin-loaded liposomes (GL), or gentamicin-loaded 
liposomes surface functionalized with InvA497 (I-GL); only a slight increase in mean liposome 
size was observed following gentamicin loading, round 200 nm in diameter. However, PDI and 
Zeta-potential were fairly similar to drug-free liposome formulations; InvA497-functionalized (I- 
L) and non-modified (L), serving as controls. Treatment with gentamicin-loaded InvA497- 
functionalized liposomes (I-GL) was seen to result in a 30% reduction in infection load – a result 
which was significantly higher than that following treatment with other control formulations 
(Figure 7). This indicates the ability of such bacteriomimetic delivery system to facilitate 
successful internalization and subsequent intracellular activity of an anti-infective drug, 
otherwise unable to cross the host cell membrane, 
 
 
4. Conclusion 
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In conclusion, the present study reports on surface functionalization of liposomes with a bacteria- 
derived invasion protein, InvA497, as a promising strategy for intracellular drug delivery. The 
successfully designed bioinvasive delivery system was shown to mimic InvA-expressing bacteria 
in its mechanism of cell adhesion and entry. As a proof of concept, InvA497-functionalized 
liposomes were loaded with gentamicin. Due to its poor permeability across cellular membranes, 
gentamicin is active against extracellular, but not against intracellular bacteria.[46] The 
incubation of such a formulation with epithelial cells, previously infected with Y. 
pseudotuberculosis, resulted in a significant reduction of intracellular bacteria. This result 
demonstrates the potential of InvA497-functionalized nanocarriers as a strategy to facilitate the 
intracellular delivery of anti-infective agents, opening new perspectives for the treatment of 
established intracellular infections by compounds otherwise incapable to reach such site of action. 
As an extension to the prototype described in this study, different bacterial adhesins of relevance 
in the infection process as well as different pharmacologically active ingredients could be 
investigated, opening new avenues to the field of drug delivery. For potential oral 
administration, additional technological measures are probably required, e.g. formulating these 
novel delivery systems in enteric-coated capsules,[47, 48]. As a further translational step, 
 
successful nanocarriers should be finally evaluated in vivo in the appropriate animal model. 
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Figure 1. Viability of HEp-2 (a), non-polarized Caco-2 (b) and polarized Caco-2 cells (c) after 
incubation with non-modified or InvA497-functionalized liposomes at a concentration of 0.12- 
1.92 μM for 4 h (HEp-2 cells) or 8 h (Caco-2 cells). 
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Figure 2. Adhesion of liposome formulations to HEp-2 cells in the presence or absence of 
InvA497- expressing Yersinia pseudotuberculosis. Representative overlaid 
fluorescence/transmission images (a) and the correspondent red channels (liposomes) (b), of 
‘late stage’ infection simulation involving bacterial incubation followed by liposome addition, 
showing DAPI-stained nuclei (blue), GFP-expressing Yersinia pseudotuberculosis (green) and 
rhodamine-labelled liposomes (red). In each case, individual images represent exposure to 
liposomes with physically adsorbed InvA497 (i), covalently linked InvA497 (ii), physically 
adsorbed BSA (iii) and covalently linked BSA (iv). (C) Numbers of HEp-2 adherent liposomes 
in the absence of Yersinia pseudotuberculosis, with simultaneous exposure to bacteria and 
following pre-incubation with bacteria. Image analysis of fluorescence images (n = 5) expressed 
as weighed number of adhering liposomes per image field. 
28  
 
 
Figure 3. Analysis of relative uptake of liposomal formulations into HEp-2 cells. (a) 
Representative overlaid confocal-multiphoton images of HEp-2 cells incubated with InvA497- 
functionalized (i, iii) and non-modified (ii, iv) liposomes for 1 h (upper panel) and 4 h (lower 
panel), indicated as red spots. Indicated are DAPI-stained nuclei (blue), Flu-WGA-stained cell 
membranes (green) and rhodamine-labelled liposomes (red). (b) Image analysis of the z- 
projection images (developed by the freeware imageJ from the imaged z-stacks) of the red 
channel showing internalized liposomes expressed as weighed number of liposomes per z-stack 
(n = 3). 
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Figure 4. Kinetic analysis of liposomal uptake into HEp-2 cells. (a) Representative Z-projection 
images of the red channel of sequestered z-stacks of living HEp-2 cells incubated with InvA497- 
functionalized liposomes (upper panel) versus non-modified liposomes (lower panel) 1, 2, 3 and 
4 h following liposome addition. Overlay images are presented for the first hour (far left image 
of each panel), additionally showing Flu-WGA-stained cell membranes in green. (b) Number of 
internalized InvA497-functionalized versus non-modified liposomes as a function of time. 
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Figure 5. Mechanistic studies of liposomal uptake. One-way ANOVA with post-hoc Tukey test 
was used to demonstrate statistical significance. (a) Uptake of non-modified and InvA- 
functionalized liposomes at both 4 °C and 37 °C was investigated, in order to determine the 
energy-dependence of formulation uptake. Significant (p value < 0.05) and very significant (p 
value < 0.01) differences from the control non-modified liposomes at 37 °C were indicated in 
figure as * and **, respectively. (b) Investigation of receptor-specific uptake of InvA497- 
functionalized liposomes by incubation of HEp-2 cells with anti-β1-integrin antibody or the InvA 
uptake inhibitors NPC-15437 or Akt inhibitor VIII, prior to liposome addition relative to control 
experiment in absence of inhibitor, indicated on figure as “no inhibitor”. Very significant 
difference (p value < 0.01) from the control experiment was indicated in figure as **. 
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Figure 6. Representative overlaid confocal-multiphoton images of Caco-2 cells, approximately 
50 % confluent (upper panel) and approximately 90 % confluent (lower panel) following 
incubation with InvA497-functionalized (a, c) and non-modified liposomes (b, d). DAPI-stained 
nuclei are indicated in blue, Flu-WGA-stained cell membranes are shown in green, and 
rhodamine-labelled liposomes are represented in red. 
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Figure 7. Anti-infective efficacy of liposome formulations. Killing percentage of Yersinia 
pseudotuberculosis-infected HEp-2 cells treated with different liposomal preparations: drug-free 
liposomes (L), InvA497-functionalized drug-free liposomes (I-L), gentamicin-loaded liposomes 
(GL) and InvA497-functionalized gentamicin-loaded liposomes (I-GL), and normalized to the 
untreated (blank, B). Significance was defined as * = p value < 0.05 
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  Table 1. Physicochemical properties of prepared liposomes.   
Liposomes Size [nm] Polydispersity 
index (PDI) 
Zeta 
potential 
[mV] 
Protein 
functionalization 
efficiency [%] 
 
 
By BCA By 
Western 
Blot 
 
 
Non-modified 144.6 ± 1.7 0.03 ± 0.02 -19.9 ± 1.7 - - 
InvA497-functionalized 143.0 ± 0.4 0.05 ± 0.01 -25.5 ± 2.62 51.5 ± 4.5 50.0 ± 2.8 
BSA- functionalized 140.6 ± 0.4 0.03 ± 0.01 -42.9 ± 0.6 43.3 ± 1.9 43.1 ± 2.9 
 
 
 
 
 
Supporting Information: 
 
 
 
 
Figure S1: Interference testing of liposomes with (Vialight
® 
Plus) viability kit in absence of 
cells. Luminescence measurement of ATP standards at 0.015 and 1.5 μM concentration in 
presence of non-modified (left Figure) and InvA497-functionalized (right Figure) liposomes was 
determined using (Vialight
® 
Plus) viability kit reagent. No significant differences (P-value > 
0.05) in luminescence values of both low and high ATP standards were observed at different 
liposomes concentration indicating lack of interference of liposomes with the assay reagent. 
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